Sort
48,018 grants matching “immunotherapy”
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$846,484James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Clinical trials employing cancer vaccine combination therapies
$846,484James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER
$846,182University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2024 · Defense Health Agency
Targeting microbial triggers of gammopathy for immunoprevention
$846,118Madhav V Dhodapkar · Fred Hutchinson Cancer Center · UG3 · FY2025 · CA
The role of BCL11B in T lineage fate during human thymopoiesis and pluripotent stem cell differentiation
$845,988Gay Miriam Crooks · University Of California Los Angeles · R01 · FY2023 · AI
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
$845,852Joseph Patti · Agilvax, Inc. · R44 · FY2019 · CA
The IL-18-IFNγ axis predicts response to immunotherapy
$845,823Heather Leigh Herd Gustafson · Seattle Children'S Hospital · R37 · FY2023 · CA
Multiplex food allergy diagnostic based on IgE immunologic markers
$845,777David Seftel · Enable Biosciences, Inc. · R44 · FY2020 · AI
Regulation of Natural Killer Cell Activation Receptors, NKG2D and CD16
$845,749John Coligan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
$845,528Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
ENGINEERING TCR-T CELLS TO TARGET HUMAN ENDOGENOUS RETROVIRUSES FOR NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY
$845,250Duke University · · FY2025 · Defense Health Agency
Single-cell Analysis of Normal and Perturbed Dynamic and Spatial Biological Systems
$845,220Benedict Anchang · National Institute Of Environmental Health Sciences · ZIA · FY2024 · ES
Defining the Mechanisms of Immune Escape After Adoptive T cell Therapies
$845,088Geoffrey Roger Hill · Fred Hutchinson Cancer Center · P01 · FY2025 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
$845,000Eliezer M Van Allen · Dana-Farber Cancer Inst · U01 · FY2021 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
$844,999Eliezer M Van Allen · Dana-Farber Cancer Inst · U01 · FY2022 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
$844,999Eliezer M Van Allen · Dana-Farber Cancer Inst · U01 · FY2020 · CA
Preclinical development of breakthrough immunotherapy for brain tumors
$844,555Hideho Okada · University Of California, San Francisco · R35 · FY2024 · NS
Multiomic strategies to assess HIV reservoir persistence
$844,008Michael R Betts · University Of Pennsylvania · R01 · FY2025 · AI
Multiomic strategies to assess HIV reservoir persistence
$844,008Michael R Betts · University Of Pennsylvania · R01 · FY2024 · AI
NOVEL IMMUNOTHERAPY COMBINATIONS AGAINST CASTRATION-RESISTANT PROSTATE CANCER
$843,940The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2019 · Defense Health Agency
UCSF Autoimmunity Center of Excellence
$843,828David Wofsy · University Of California, San Francisco · U19 · FY2006 · AI
SUPERCOOLED EX-VIVO PORCINE VCA PRESERVATION TO EXTEND THE TIMELINE BETWEEN PROCUREMENT AND TRANSPLANTATION AND ENABLE TOLERANCE INDUCTION TO ELIMINATE IMMUNOTHERAPY NEEDS AND RISKS.
$843,746The General Hospital Corporation · · FY2019 · Defense Health Agency
Human antibodies as broad alphavirus immunotherapeutics
$843,620Jonathan R. Lai · Albert Einstein College Of Medicine · R01 · FY2025 · AI
A new humanized mouse model to study HBV gene editing
$843,440Keith R Jerome · Fred Hutchinson Cancer Center · R01 · FY2025 · AI
Role of Tumor Stroma in Therapeutic Response and Resistance
$843,318Phillip Andrew Futreal · University Of Tx Md Anderson Can Ctr · U54 · FY2015 · CA